查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587512

高度活躍的 API契約製造市場規模、佔有率、趨勢分析報告：按產品、劑型、應用、合成、區域、細分市場預測，2025-2030 年

High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Innovative, Generic), By Dosage Form (Injectable, Creams), By Application, By Synthesis, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

高度活躍的 API契約製造市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球高活性API契約製造市場規模預計將達到148.7億美元，預測期內複合年成長率為10.98%。

該市場的主要促進因素是癌症治療需求的不斷成長、製造技術的進步以及產能的提高以滿足不斷成長的需求。此外，治療慢性病的標靶治療的興起可能會加速該行業的成長。 COVID-19 大流行增加了對高活性原料藥(HPAPI) 的需求。疫情上半年擾亂了供應鏈並減少了研究活動。

然而，下半年，由於對抗冠狀病毒的疫苗需求增加，該行業開始變得越來越重要。這種成長也增加了API分子的原料和產品中間體的需求。此外，COVID-19 大流行期間對 HPAPI 分子的需求增加導致相同分子的價格上漲，從而推動了 2020 年和 2021 年的收益成長。高活性藥物的外包正在增加，因為它消除了投資昂貴的基礎設施來遏制它們的需求。

另外，設備的安裝和維護比較複雜，需要專門的工程師。內部生產高活性原料藥的成本高昂，加上生產負擔得起的藥物的壓力，大大促進了公司外包活動的增加。大量的外包供應商提供 HPAPI 服務，這使得企業很難選擇合適的 CDMO。能夠大規模生產的大規模CDMO是最有可能的選擇。然而，規模較小的醫療服務提供者也變得越來越重要，因為他們需要的劑量較少。

高度活躍的 API契約製造市場報告亮點

  • 產品類型分為創新和非專利。 2024 年，創新業務佔據最大的收益佔有率。
  • 從應用來看，由於新的癌症藥物和治療方法的研究不斷增加，腫瘤學將在 2024 年佔據該行業的主導地位。
  • 預計口服固態製劑領域在預測期內將呈現最快的成長速度。
  • 按合成，該行業分為合成和生物技術。預計 2025 年至 2030 年生技產業將呈現顯著成長。
  • 由於中國等全球最大的原料藥製造商的存在，亞太地區預計在預測期內複合年成長率最快。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 高度活躍的 API契約製造市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望。
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 高度活躍的 API契約製造市場：產品預估及趨勢分析

  • 細分儀表板
  • 全球高度活躍的API契約製造市場：波動分析
  • 2018-2030年全球高活躍API契約製造規模及趨勢分析
  • 創新的
  • 非專利的

第5章 高度活躍的 API契約製造市場：應用預估與趨勢分析

  • 細分儀表板
  • 全球高度活躍的API契約製造市場：波動分析
  • 2018-2030年全球高活躍API契約製造規模及趨勢分析
  • 腫瘤學
  • 荷爾蒙失調
    • 青光眼
    • 其他

第6章 高度活躍的API契約製造市場：綜合估算與趨勢分析

  • 細分儀表板
  • 全球高度活躍的API契約製造市場：波動分析
  • 2018-2030年全球高活躍API契約製造規模及趨勢分析
  • 合成
  • 生物技術

第7章 高度活躍的API契約製造市場：劑型估算及趨勢分析

  • 細分儀表板
  • 全球高度活躍的API契約製造市場：波動分析
  • 2018-2030年全球高活躍API契約製造規模及趨勢分析
  • 可注射的
  • 口服固態
  • 奶油
  • 其他

第8章 高度活躍的API契約製造市場：區域估算與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • Piramal Pharma Solutions
    • Lonza
    • Catalent Inc
    • VxP Pharma, Inc.
    • Pfizer CentreOne
    • Gentec Pharmaceutical Group
    • AbbVie
    • Aurigene Pharmaceutical Services Ltd.
    • CordenPharma International
    • Curia Global, Inc.
Product Code: GVR-4-68039-970-5

High Potency API Contract Manufacturing Market Growth & Trends:

The global high potency API contract manufacturing market size is expected to reach USD 14.87 billion by 2030, registering a CAGR of 10.98% over the forecast period, according to a new report by Grand View Research, Inc. The main drivers of this market are rising demand for oncology drugs, advancements in manufacturing technology, and a rise in capacity to meet the increasing demand. Also, a rise in target therapies to cure chronic diseases is going to accelerate industry growth. The COVID-19 pandemic boosted the demand for high potency APIs (HPAPIs). During the first half of the pandemic, the supply chain was disrupted, which reduced research-based activities.

However, during the second half, the industry started to gain importance due to a rise in demand for vaccines to fight the coronavirus. This rise has also increased the demand for raw materials and product intermediates of API molecules. Moreover, the growing demand for HPAPI molecules during the COVID-19 pandemic has led to the price hike of the same, thus boosting revenue growth in 2020 and 2021. There has been a rise in the outsourcing activities of high potency active pharmaceuticals as it removes the need for investment in expensive infrastructure for containing it.

Also, the installation & maintenance of the facility is complex and requires specialized engineers. The high cost of producing high potency API in-house, combined with the pressure to produce affordable drugs, has significantly contributed to the increasing outsourcing activities by companies. A wide range of outsourcing providers offers HPAPI services, thus making it difficult for companies to choose an appropriate CDMO. The large-scale CDMOs become the most likely choice as they provide large volumes. However, due to the small volumes required for dosage, small-scale providers are also gaining importance.

High Potency API Contract Manufacturing Market Report Highlights:

  • The product type segment is classified into innovative and generic. The innovative segment accounted for the largest revenue share in 2024
  • Based on applications, the oncology segment dominated the industry in 2024 due to a rise in research on new cancer drugs and therapies
  • The oral solids dosage form segment is anticipated to witness the fastest growth rate during the forecast period
  • By synthesis, the industry is classified into synthetic and biotech. The biotech segment is estimated to witness a significant growth rate from 2025 to 2030
  • The Asia Pacific region is estimated to register the fastest CAGR during the forecast period due to the presence of the largest manufacturers of APIs across the globe, such as China

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. High Potency API Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing pipeline of pharmaceutical drugs
      • 3.2.1.2. Growing expansion of HPAPI production facilities
      • 3.2.1.3. Increasing trend of outsourcing
      • 3.2.1.4. Increasing application of HPAPIs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Significant investments and complicated safety and handling specifications associated with the production of HPAPIs
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. High Potency API Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global High Potency API Contract Manufacturing Market; Product Movement Analysis
  • 4.3. Global High Potency API Contract Manufacturing Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Innovative
    • 4.4.1. Innovative market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. High Potency API Contract Manufacturing Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global High Potency API Contract Manufacturing Market; Application Movement Analysis
  • 5.3. Global High Potency API Contract Manufacturing Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Hormonal Disorders
    • 5.5.1. Hormonal disorders market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Glaucoma
      • 5.5.2.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Others
      • 5.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. High Potency API Contract Manufacturing Market: Synthesis Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global High Potency API Contract Manufacturing Market; Synthesis Movement Analysis
  • 6.3. Global High Potency API Contract Manufacturing Size & Trend Analysis, by Synthesis, 2018 to 2030 (USD Million)
  • 6.4. Synthetic
    • 6.4.1. Synthetic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Biotech
    • 6.5.1. Biotech market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. High Potency API Contract Manufacturing Market: Dosage Form Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global High Potency API Contract Manufacturing Market; Dosage Form Movement Analysis
  • 7.3. Global High Potency API Contract Manufacturing Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
  • 7.4. Injectable
    • 7.4.1. Injectable market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Oral Solids
    • 7.5.1. Oral Solids market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Creams
    • 7.6.1. Creams market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. High Potency API Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. North America
    • 8.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Competitive scenario
      • 8.3.2.3. Regulatory framework
      • 8.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Competitive scenario
      • 8.3.3.3. Regulatory framework
      • 8.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key country dynamics
      • 8.3.4.2. Competitive scenario
      • 8.3.4.3. Regulatory framework
      • 8.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory framework
      • 8.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Competitive scenario
      • 8.4.5.3. Regulatory framework
      • 8.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Competitive scenario
      • 8.4.6.3. Regulatory framework
      • 8.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Competitive scenario
      • 8.4.7.3. Regulatory framework
      • 8.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Competitive scenario
      • 8.4.8.3. Regulatory framework
      • 8.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key country dynamics
      • 8.4.9.2. Competitive scenario
      • 8.4.9.3. Regulatory framework
      • 8.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. South Korea
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory framework
      • 8.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Thailand
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory framework
      • 8.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. Regulatory framework
      • 8.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Competitive scenario
      • 8.7.5.3. Regulatory framework
      • 8.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Piramal Pharma Solutions
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Lonza
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Catalent Inc
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. VxP Pharma, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Pfizer CentreOne
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Gentec Pharmaceutical Group
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. AbbVie
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Aurigene Pharmaceutical Services Ltd.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. CordenPharma International
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Curia Global, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 4 Global High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 5 Global High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 6 Global High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 7 Global High Potency API Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America High Potency API Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 10 North America High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 11 Global High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 12 Global High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 13 U.S. High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 14 U.S. High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 15 U.S. High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 16 U.S. High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 17 Canada High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 18 Canada High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 19 Canada High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 20 Canada High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 21 Mexico High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 22 Mexico High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 23 Mexico High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 24 Mexico High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 25 UK High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 26 UK High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 27 UK High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 28 UK High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 29 Germany High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 30 Germany High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 31 Germany High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 32 Germany High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 33 France High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 34 France High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 35 France High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 36 France High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 37 Italy High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 38 Italy High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 39 Italy High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 40 Italy High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 41 Spain High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 42 Spain High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 43 Spain High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 44 Spain High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 45 Sweden High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 46 Sweden High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 47 Sweden High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 48 Sweden High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 49 Norway High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 50 Norway High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 51 Norway High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 52 Norway High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 53 Denmark High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 54 Denmark High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 55 Denmark High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 56 Denmark High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 57 India High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 58 India High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 59 India High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 60 India High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 61 China High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 62 China High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 63 China High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 64 China High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 65 Japan High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 66 Japan High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 67 Japan High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 68 Japan High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 69 India High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 70 India High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 71 India High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 72 India High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 73 Australia High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 74 Australia High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 75 Australia High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 76 Australia High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 77 Thailand High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 78 Thailand High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 79 Thailand High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 80 Thailand High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 81 South Korea High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 82 South Korea High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 83 South Korea High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 84 South Korea High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 85 Brazil High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 86 Brazil High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 87 Brazil High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 88 Brazil High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 89 Argentina High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 90 Argentina High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 91 Argentina High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 92 Argentina High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 96 Saudi Arabia High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 97 UAE High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 98 UAE High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 99 UAE High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 100 UAE High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)
  • Table 101 Kuwait High Potency API Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 102 Kuwait High Potency API Contract Manufacturing, by Synthesis, 2018 - 2030 (USD Million)
  • Table 103 Kuwait High Potency API Contract Manufacturing, by Application, 2018 - 2030 (USD Million)
  • Table 104 Kuwait High Potency API Contract Manufacturing, by Dosage Form, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 High Potency API Contract Manufacturing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 13 Global High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 14 Global Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 15 Global pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 16 Global Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 17 Global Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 18 Global Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 19 Global Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 20 Global Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 21 Global Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 22 Global Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 23 Global Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 24 Global Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 25 North America High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 26 North America High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 27 North America Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 28 North America Pharmaceutical Stability Services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 29 North America Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 30 North America Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 31 North America Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 32 North America Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 33 North America Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 34 North America Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 35 North America Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 36 North America Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 37 North America Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 38 U.S. High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 49 U.S. Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 51 Canada High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 52 Canada High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 53 Canada Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 54 Canada pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 55 Canada Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 56 Canada Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 57 Canada Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 58 Canada Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 59 Canada Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 60 Canada Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 61 Canada Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 62 Canada Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 63 Canada Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 64 Mexico High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 65 Mexico High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 66 Mexico Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 67 Mexico pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 70 Mexico Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 71 Mexico Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 72 Mexico Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 74 Mexico Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 75 Mexico Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 76 Mexico Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 77 Europe High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 78 Europe High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 79 Europe Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 80 Europe pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 81 Europe Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 82 Europe Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 83 Europe Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 84 Europe Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 85 Europe Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 86 Europe Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 87 Europe Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 88 Europe Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 89 Europe Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 90 UK High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 91 UK High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 92 UK Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 93 UK pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 94 UK Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 95 UK Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 96 UK Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 97 UK Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 98 UK Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 99 UK Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 100 UK Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 101 UK Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 102 UK Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 103 Germany High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 104 Germany High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 105 Germany Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 106 Germany pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 107 Germany Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 108 Germany Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 109 Germany Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 110 Germany Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 111 Germany Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 112 Germany Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 113 Germany Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 114 Germany Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 115 Germany Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 116 France High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 117 France High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 118 France Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 119 France pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 120 France Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 121 France Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 122 France Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 123 France Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 124 France Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 125 France Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 126 France Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 127 France Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 128 France Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 129 Italy High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 130 Italy High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 131 Italy Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 132 Italy pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 133 Italy Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 134 Italy Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 135 Italy Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 136 Italy Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 137 Italy Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 138 Italy Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 139 Italy Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 140 Italy Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 141 Italy Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 142 Spain High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 143 Spain High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 144 Spain Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 145 Spain pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 146 Spain Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 147 Spain Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 148 Spain Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 149 Spain Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 150 Spain Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 151 Spain Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 152 Spain Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 153 Spain Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 154 Spain Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 155 Denmark High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 156 Denmark High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 157 Denmark Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 158 Denmark pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 159 Denmark Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 160 Denmark Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 161 Denmark Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 162 Denmark Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 163 Denmark Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 164 Denmark Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 165 Denmark Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 166 Denmark Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 167 Denmark Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 168 Sweden High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 169 Sweden High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 170 Sweden Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 171 Sweden pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 172 Sweden Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 173 Sweden Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 174 Sweden Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 175 Sweden Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 176 Sweden Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 177 Sweden Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 178 Sweden Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 179 Sweden Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 180 Sweden Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 181 Norway High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 182 Norway High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 183 Norway Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 184 Norway pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 185 Norway Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 186 Norway Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 187 Norway Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 188 Norway Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 189 Norway Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 190 Norway Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 191 Norway Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 192 Norway Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 193 Norway Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 194 Asia Pacific High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 195 Asia Pacific High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 196 Asia Pacific Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 197 Asia Pacific pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 198 Asia Pacific Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 199 Asia Pacific Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 200 Asia Pacific Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 201 Asia Pacific Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 202 Asia Pacific Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 203 Asia Pacific Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 204 Asia Pacific Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 205 Asia Pacific Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 206 Asia Pacific Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 207 Japan High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 208 Japan High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 209 Japan Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 210 Japan pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 211 Japan Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 212 Japan Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 213 Japan Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 214 Japan Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 215 Japan Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 216 Japan Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 217 Japan Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 218 Japan Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 219 Japan Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 220 China High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 221 China High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 222 China Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 223 China pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 224 China Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 225 China Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 226 China Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 227 China Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 228 China Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 229 China Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 230 China Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 231 China Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 232 China Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 233 India High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 234 India High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 235 India Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 236 India pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 237 India Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 238 India Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 239 India Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 240 India Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 241 India Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 242 India Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 243 India Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 244 India Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 245 India Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 246 Australia High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 247 Australia High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 248 Australia Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 249 Australia pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 250 Australia Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 251 Australia Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 252 Australia Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 253 Australia Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 254 Australia Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 255 Australia Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 256 Australia Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 257 Australia Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 258 Australia Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 259 South Korea High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 260 South Korea High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 261 South Korea Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 262 South Korea pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 263 South Korea Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 264 South Korea Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 265 South Korea Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 266 South Korea Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 267 South Korea Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 268 South Korea Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 269 South Korea Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 270 South Korea Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 271 South Korea Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 272 Thailand High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 273 Thailand High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 274 Thailand Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 275 Thailand pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 276 Thailand Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 277 Thailand Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 278 Thailand Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 279 Thailand Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 280 Thailand Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 281 Thailand Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 282 Thailand Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 283 Thailand Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 284 Thailand Large Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 285 Latin America High Potency API Contract Manufacturing, for Product, 2018 - 2030 (USD Million)
  • Fig. 286 Latin America High Potency API Contract Manufacturing, for Application, 2018 - 2030 (USD Million)
  • Fig. 287 Latin America Pharmaceutical Stability Services, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 288 Latin America pharmaceutical stability services, for Stability Indicating Method Validation, 2018 - 2030 (USD Million)
  • Fig. 289 Latin America Pharmaceutical Stability Services, For Accelerated Stability Testing, 2018 - 2030 (USD Million)
  • Fig. 290 Latin America Pharmaceutical Stability Services, For Photostability Testing, 2018 - 2030 (USD Million)
  • Fig. 291 Latin America Pharmaceutical Stability Services, For Other Stability Testing Methods, 2018 - 2030 (USD Million)
  • Fig. 292 Latin America Pharmaceutical Storage Services, for Cold, 2018 - 2030 (USD Million)
  • Fig. 293 Latin America Pharmaceutical Storage Services, for Non-cold, 2018 - 2030 (USD Million)
  • Fig. 294 Latin America Small Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 295 Latin America Small Molecule High Potency API Contract Manufacturing, for Commercial Products
  • Fig. 296 Latin America Large Molecule High Potency API Contract Manufacturing, for Research Products, 2018 - 2030 (USD Million)
  • Fig. 297 Latin America Large Molecule High Potency API Contract Manufacturing, for Commercial Products